Clearside Historical Financial Ratios
| CLSD Stock | USD 1.05 0.02 1.87% |
Clearside Biomedical is presently reporting on over 104 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 8.24 or Invested Capital of 0.0 will help investors to properly organize and evaluate Clearside Biomedical financial condition quickly.
Clearside |
About Clearside Financial Ratios Analysis
Clearside BiomedicalFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Clearside Biomedical investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Clearside financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Clearside Biomedical history.
Clearside Biomedical Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Clearside Biomedical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Clearside Biomedical sales, a figure that is much harder to manipulate than other Clearside Biomedical multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Clearside Biomedical's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Clearside Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.At present, Clearside Biomedical's Income Quality is projected to drop slightly based on the last few years of reporting. The current year's ROE is expected to grow to 2.14, whereas PTB Ratio is projected to grow to (4.32).
| 2010 | 2023 | 2024 (projected) | Payables Turnover | 0.0225 | 0.16 | 0.11 | Days Of Inventory On Hand | 1.9K | 1.7K | 1.5K |
Clearside Biomedical fundamentals Correlations
Click cells to compare fundamentals
Clearside Biomedical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Clearside Biomedical fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 50.94 | 16.14 | 5.44 | 50.81 | 8.79 | 8.35 | |
| Ptb Ratio | 9.92 | 14.54 | 4.24 | 6.36 | (4.54) | (4.32) | |
| Book Value Per Share | 0.29 | 0.19 | 0.65 | 0.18 | (0.26) | (0.24) | |
| Free Cash Flow Yield | (0.29) | (2.41) | (0.24) | (0.0667) | (0.2) | (0.28) | |
| Operating Cash Flow Per Share | (0.71) | (0.28) | (0.18) | (0.22) | (0.29) | (0.31) | |
| Stock Based Compensation To Revenue | 2.12 | 0.46 | 0.17 | 3.68 | 0.51 | 0.49 | |
| Capex To Depreciation | 0.47 | 0.12 | 0.31 | 1.7 | 26.52 | 27.85 | |
| Pb Ratio | 9.92 | 14.54 | 4.24 | 6.36 | (4.54) | (4.32) | |
| Ev To Sales | 43.49 | 14.2 | 4.43 | 15.42 | 10.5 | 9.98 | |
| Free Cash Flow Per Share | (0.71) | (0.28) | (0.18) | (0.23) | (0.32) | (0.34) | |
| Roic | (1.81) | (1.75) | (0.0189) | (2.86) | (0.94) | (0.99) | |
| Net Income Per Share | (0.8) | (0.39) | 0.006428 | (0.57) | (0.53) | (0.55) | |
| Sales General And Administrative To Revenue | 7.74 | 1.36 | 0.39 | 8.87 | 1.44 | 1.37 | |
| Research And Ddevelopement To Revenue | 7.21 | 1.91 | 0.63 | 14.79 | 2.53 | 2.41 | |
| Capex To Revenue | 2.93 | 0.0115 | 0.006967 | 0.19 | 0.22 | 0.21 | |
| Cash Per Share | 0.59 | 0.37 | 0.52 | 0.8 | 0.47 | 0.44 | |
| Pocfratio | (4.09) | (9.71) | (14.99) | (5.05) | (3.99) | (4.19) | |
| Capex To Operating Cash Flow | (0.001111) | (9.24E-4) | (0.004192) | (0.0184) | (0.098) | (0.0931) | |
| Pfcf Ratio | (4.09) | (9.67) | (14.99) | (4.95) | (3.63) | (3.81) | |
| Roe | (2.74) | (2.06) | 0.009901 | (3.21) | 2.04 | 2.14 | |
| Ev To Operating Cash Flow | (3.49) | (8.55) | (12.21) | (1.53) | (4.76) | (5.0) | |
| Pe Ratio | (3.62) | (7.07) | 427.8 | (1.98) | (2.23) | (2.11) | |
| Return On Tangible Assets | (1.14) | (0.93) | 0.008764 | (0.66) | (0.95) | (1.0) | |
| Ev To Free Cash Flow | (3.49) | (8.51) | (12.21) | (1.5) | (4.34) | (4.56) | |
| Earnings Yield | (0.28) | (0.14) | 0.002338 | (0.51) | (0.45) | (0.47) | |
| Current Ratio | 2.31 | 1.82 | 9.08 | 8.34 | 4.42 | 4.02 | |
| Tangible Book Value Per Share | 0.29 | 0.19 | 0.65 | 0.18 | (0.26) | (0.24) | |
| Graham Number | 2.29 | 1.28 | 0.31 | 1.5 | 1.74 | 1.66 | |
| Shareholders Equity Per Share | 0.29 | 0.19 | 0.65 | 0.18 | (0.26) | (0.24) | |
| Debt To Equity | 0.49 | 0.16 | 0.0102 | 0.0329 | (2.66) | (2.53) | |
| Capex Per Share | 0.002863 | 6.55E-4 | 0.001183 | 0.004086 | 0.0288 | 0.0302 | |
| Graham Net Net | 0.18 | 0.14 | 0.57 | 0.13 | (0.34) | (0.32) | |
| Revenue Per Share | 0.0569 | 0.17 | 0.51 | 0.022 | 0.13 | 0.096 | |
| Interest Debt Per Share | 0.17 | 0.0365 | 0.006616 | 0.0613 | 0.84 | 0.88 | |
| Debt To Assets | 0.21 | 0.0706 | 0.00902 | 0.006803 | 1.24 | 1.31 | |
| Enterprise Value Over E B I T D A | (3.14) | (6.25) | (291.96) | (0.69) | (3.75) | (3.93) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearside Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.91) | Return On Assets (0.44) | Return On Equity (13.10) |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.